A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

NCT03347396 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Agglutinin Disease, Cold

Interventions

DRUG: BIVV009

Sponsor

Bioverativ, a Sanofi company